TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03602300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir test formulation produced by Doppel
Description: To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ravidasvir reference formulation produced by EEPI
Description: To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions.
Study: NCT02734498

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Treatment (ECT) Right Unilateral
Description: Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed unilateral on the right side.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Treatment (ECT) - Bilateral
Description: Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed Bilateral.
Study: NCT00992043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: creatine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training
Study: NCT01215487

Intervention type: PROCEDURE
Intervention: Stem Cell and Mutational Assay
Description: Laboratory blood testing
Study: NCT02022787

Intervention type: OTHER
Intervention: patients with renal cell carcinoma
Description: Chemokines that may be elevated in patients with RCC
Study: NCT04045964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy (NRT)
Description: Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational advice
Description: Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quitline referral
Description: Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
Study: NCT00248209

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wellbutrin XL
Description: Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
Study: NCT01516723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)
Description: Recanalization of totally occluded coronary arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)
Description: Recanalization of totally occluded coronary arteries
Study: NCT03718715

Intervention type: DRUG
Intervention: Metformin
Description: Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
Study: NCT01877161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive magnetic stimulation to superior temporal gyrus
Description: Repetitive magnetic stimulation to superior temporal gyrus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive magnetic stimulation to middle temporal gyrus
Description: Repetitive magnetic stimulation to middle temporal gyrus

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive magnetic stimulation (Sham)
Description: Repetitive magnetic stimulation (Sham)
Study: NCT01886508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve-spring radical hysterectomy
Description: Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical hysterectomy
Description: Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
Study: NCT02589145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 1000 mg by mouth on Days -9 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m2 by vein on days -3 and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg by vein twice a day from Day -8 AM to Day -2 PM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 100 mg by vein or mouth three times a day from Day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell transplant performed on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
Study: NCT02731300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: brain stimulation by cathodal electrode at motor cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: brain stimulation by cathodal electrode at motor cortex
Study: NCT00768690

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
Study: NCT01896427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione
Description: single dose of dexamethasone (8mg) will injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione
Description: single dose of dexamethasone (8mg) will injected
Study: NCT01933243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Participants will take 4 capsules daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Participants will take 4 capsules daily
Study: NCT01868932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypertonic saline
Description: inhaled nebulized 3%NaCl

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: inhaled nebulized 0.9% NaCl
Study: NCT03237442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: human UC-MSCs: 0.2ml(about 2\*10\^6 cells) subconjunctival injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Saline injection
Study: NCT00449605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Tablet, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin continued at stable dose as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin continued at stable dose as background therapy
Study: NCT02580929

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy before surgery
Study: NCT04776642

Intervention type: OTHER
Intervention: Biobank for Left atrial appendage tissue
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for Left atrial appendage tissue
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for Left atrial appendage tissue
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for Blood
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for Blood
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for Blood
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for Blood
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for Blood
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for Blood
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for Blood
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
Study: NCT00768690

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.

Intervention type: DRUG
Group type: OTHER
Intervention: ketoconazole
Description: Tablet, see arms for intervention description

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
Study: NCT04007328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Sodium Succinate
Description: methylprednisolone vial
Study: NCT04776642

Intervention type: OTHER
Intervention: Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.

Intervention type: OTHER
Intervention: Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
Study: NCT02056353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOGIC-Insulin algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paper protocol
Study: NCT01660386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100mg po once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5mg po once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: 2mg po once

Intervention type: DRUG
Group type: OTHER
Intervention: Blank control
Description: the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
Study: NCT00412412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNF2024
Description: Oral doses of CNF2024 as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNF2024 + trastuzumab
Description: Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
Study: NCT00349934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMP321
Description: This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy.
Study: NCT01071655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX
Description: BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BVZ+XELOX
Description: BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
Study: NCT01144052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon beta-1b
Description: Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units \[MIU\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natalizumab
Description: Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
Study: NCT01576380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
Study: NCT03454841

Intervention type: DRUG
Intervention: Prasugrel
Description: Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily

Intervention type: DRUG
Intervention: Ticagrelor
Description: Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
Study: NCT01534065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barricaid
Description: Implanted intra-operatively during discectomy
Study: NCT00733876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multipotent Stromal Cells
Description: Post-operative administration of MSC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of MSC
Description: Dose escalation protocol
Study: NCT03215940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delta-9-Tetrahydrocannabinol
Description: An oral dose of Delta-9-Tetrahydrocannabinol (THC) will be given once a day for five day with pain ratings taken before and after each dose every day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
Study: NCT03098563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded study medication
Description: Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded study medication
Description: Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded study medication
Description: Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded study medication
Description: Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
Study: NCT02383940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin 400 mg, once daily before the first meal of the day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily before the first meal of the day
Study: NCT00685698

Intervention type: DRUG
Group type: OTHER
Intervention: TG-873870 (Nemonoxacin)
Description: 750 mg
Study: NCT04239469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KL16-012
Description: Standardized cannabis sativa extract of THC and CBD, with each drop containing 1 mg of THC and 0.45 mg of CBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo